EA200400755A1 - ТЕРАПИЯ ГЛИОБЛАСТОМЫ ТИМОЗИНОМ-α1 - Google Patents

ТЕРАПИЯ ГЛИОБЛАСТОМЫ ТИМОЗИНОМ-α1

Info

Publication number
EA200400755A1
EA200400755A1 EA200400755A EA200400755A EA200400755A1 EA 200400755 A1 EA200400755 A1 EA 200400755A1 EA 200400755 A EA200400755 A EA 200400755A EA 200400755 A EA200400755 A EA 200400755A EA 200400755 A1 EA200400755 A1 EA 200400755A1
Authority
EA
Eurasian Patent Office
Prior art keywords
thyrozynom
glioblastoma therapy
glioblastoma
therapy
alpha1
Prior art date
Application number
EA200400755A
Other languages
English (en)
Other versions
EA005822B1 (ru
Inventor
Джек Р. Уандс
Сузанна Де Ля Монте
Original Assignee
Роуд Айлэнд Хоспитал
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Роуд Айлэнд Хоспитал filed Critical Роуд Айлэнд Хоспитал
Publication of EA200400755A1 publication Critical patent/EA200400755A1/ru
Publication of EA005822B1 publication Critical patent/EA005822B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Prostheses (AREA)

Abstract

Тимозин-α1 применяется в качестве адъюванта в комбинации с кармустином (BCNU) в качестве эффективной терапии злокачественной глиобластомы.Отчет о международном поиске был опубликован 2004.01.15.
EA200400755A 2001-12-10 2002-12-10 ТЕРАПИЯ ГЛИОБЛАСТОМЫ ТИМОЗИНОМ -α1 EA005822B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33714901P 2001-12-10 2001-12-10
PCT/US2002/039329 WO2003049697A2 (en) 2001-12-10 2002-12-10 Treatment of glioblastoma with thymosin-alpha 1

Publications (2)

Publication Number Publication Date
EA200400755A1 true EA200400755A1 (ru) 2004-12-30
EA005822B1 EA005822B1 (ru) 2005-06-30

Family

ID=23319320

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400755A EA005822B1 (ru) 2001-12-10 2002-12-10 ТЕРАПИЯ ГЛИОБЛАСТОМЫ ТИМОЗИНОМ -α1

Country Status (22)

Country Link
US (1) US20060166870A1 (ru)
EP (1) EP1461063B1 (ru)
JP (1) JP2005516910A (ru)
KR (2) KR20040091611A (ru)
CN (1) CN1615147A (ru)
AT (1) ATE356628T1 (ru)
AU (1) AU2002357115B2 (ru)
BR (1) BR0214848A (ru)
CA (1) CA2469595A1 (ru)
DE (1) DE60218896T2 (ru)
DK (1) DK1461063T3 (ru)
EA (1) EA005822B1 (ru)
ES (1) ES2283653T3 (ru)
IL (1) IL162434A0 (ru)
MX (1) MXPA04005585A (ru)
NO (1) NO20042927L (ru)
NZ (1) NZ533942A (ru)
PL (1) PL370829A1 (ru)
PT (1) PT1461063E (ru)
SI (1) SI1461063T1 (ru)
UA (1) UA77999C2 (ru)
WO (1) WO2003049697A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2288118B1 (es) 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
CN108226016A (zh) * 2018-01-12 2018-06-29 浙江普罗亭健康科技有限公司 肿瘤免疫细胞亚群精准分型的质谱流式检测试剂盒
CN112147326B (zh) * 2020-09-04 2022-04-08 北京大学 一种肿瘤免疫细胞亚群分型精准检测试剂盒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) * 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
US4148786A (en) * 1978-06-26 1979-04-10 American Home Products Corporation Analgesic polypeptide
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
IT1238231B (it) * 1989-12-18 1993-07-12 Consiglio Nazionale Ricerche Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
FR2793684B1 (fr) * 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
US6462017B1 (en) * 2000-05-01 2002-10-08 Sciclone Pharmaceuticals, Inc. Method of reducing side effects of chemotherapy in cancer patients

Also Published As

Publication number Publication date
SI1461063T1 (sl) 2007-08-31
JP2005516910A (ja) 2005-06-09
AU2002357115B2 (en) 2007-12-13
DE60218896T2 (de) 2007-09-20
ES2283653T3 (es) 2007-11-01
IL162434A0 (en) 2005-11-20
PT1461063E (pt) 2007-06-18
EP1461063A2 (en) 2004-09-29
EP1461063A4 (en) 2005-08-31
DE60218896D1 (de) 2007-04-26
NZ533942A (en) 2007-01-26
WO2003049697A3 (en) 2004-01-15
WO2003049697A2 (en) 2003-06-19
EA005822B1 (ru) 2005-06-30
MXPA04005585A (es) 2005-03-23
AU2002357115A1 (en) 2003-06-23
EP1461063B1 (en) 2007-03-14
CA2469595A1 (en) 2003-06-19
PL370829A1 (en) 2005-05-30
KR20100029844A (ko) 2010-03-17
US20060166870A1 (en) 2006-07-27
DK1461063T3 (da) 2007-05-21
UA77999C2 (en) 2007-02-15
ATE356628T1 (de) 2007-04-15
CN1615147A (zh) 2005-05-11
BR0214848A (pt) 2004-11-09
NO20042927L (no) 2004-09-09
KR20040091611A (ko) 2004-10-28

Similar Documents

Publication Publication Date Title
ATE461217T1 (de) Glp-1-verbindungen
TR200504892A1 (tr) Belirti göstermeyen tüberküloz tedavisi
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
NO20042657L (no) Syreloselig hoyfluidtapspille for tapt sirkulasjon
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
ATE515514T1 (de) Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
ITMO20010008A0 (it) Dispositivo per trattamenti cutanei
CY1108540T1 (el) Ταυτοποιηση θεραπευτικων ενωσεων
HRP20090513T1 (en) S-mirtazapine for the treatment of hot flush
SE0301650D0 (sv) Novel compounds
SE0302304D0 (sv) Novel compounds
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
ATE399532T1 (de) Medizinische seife
IS2254B (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
EA200400755A1 (ru) ТЕРАПИЯ ГЛИОБЛАСТОМЫ ТИМОЗИНОМ-α1
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
TR200200169T2 (tr) IL-18 inhibitörlerinin kullanımı.
DE60122559D1 (de) Indolderivate als pde5-inhibitoren
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer
SE0302361D0 (sv) Inhibering av upptagning av monoamin
BR0308976A (pt) Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia
NO20062138L (no) Anvendelse av ifenprodil i behandling av smerte

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU